The $130bn obesity drug market has an insurance problem

Goldman Sachs estimates the obesity-drug market to reach $130bn by 2030, up from an October forecast of $100bn. While demand for these drugs continues to rise, the high cost of GLP-1 medications has led some insurance companies and employers to limit or completely halt coverage. Bloomberg investigates.